(Reuters) -Pfizer Inc and associate BioNTech have accomplished the submitting with the U.S. medication regulator in search of authorization for his or her COVID-19 vaccine in youngsters beneath 5 years of age.

The submitting with the U.S. Meals and Drug Administration (FDA), accomplished on Wednesday, included information exhibiting three lower-dose pictures of the vaccine generated a robust immune response in youngsters as younger as 6 months of age.

No COVID-19 shot is but accepted for kids in that age group in most elements of the world. It stays unclear what number of dad and mom will get their younger ones vaccinated as demand has been low in children aged 5 to 11.

Pfizer (NYSE:) and BioNTech on Might 23 mentioned their trial confirmed a 3 microgram model of the vaccine generated an analogous immune response in beneath 5-year-olds as two doses of 30 micrograms every in 16 to 25-year-olds in an earlier trial.

Rival Moderna (NASDAQ:) in March launched trial information that confirmed a two-dose formulation of its vaccine was protected and generated an analogous immune response in younger youngsters as in adults.

The FDA’s impartial advisers will talk about the 2 functions in a gathering set for June 15.